TransMedics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stag...
Latest News
4 days ago · prnewswire.com
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
5 days ago · seekingalpha.com
TransMedics: 2027 Setting Up To Be A Pivotal YearTransMedics Group is reiterated as a 'strong buy' due to compelling valuation and significant upside potential tied to multi-organ platform expansion. TMDX's 2027 catalysts include ENHANCE Heart, DENOVO Lung, CHOPS, OCS Kidney, and European expansion, all critical for achieving ambitious transplant volume targets. Q3 2026 saw record $203M revenue (+41% YoY), with management raising 2026 guidance to $764–$774M and operating margins expected at 12.5%–14%.
6 days ago · zacks.com
TransMedics (TMDX) Just Reclaimed the 200-Day Moving AverageTransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 200-day moving average, which suggests a long-term bullish trend.
6 days ago · seekingalpha.com
TransMedics: Growth Is Accelerating Again And 2027 Looks PromisingTransMedics Group Inc. demonstrates accelerating revenue growth, improved service margins, and market share gains in the recent quarter. TransMedics raised full-year revenue guidance to $764-774 million, with organic growth of 24-26% and service revenue up 60% YoY. Key 2027 growth catalysts include European expansion, new heart and lung programs, and the early-stage kidney opportunity.
7 days ago · fool.com
TransMedics: 3 Key Takeaways for Long-Term InvestorsTransMedics raised 2026 revenue guidance to $764 million to $774 million. Third-quarter revenue reached $203 million, up 41% year over year.
8 days ago · zacks.com
TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 20-day moving average, which suggests a short-term bullish trend.
8 days ago · zacks.com
TransMedics (TMDX) Recently Broke Out Above the 50-Day Moving AverageFrom a technical perspective, TransMedics (TMDX) is looking like an interesting pick, as it just reached a key level of support. TMDX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
10 days ago · marketbeat.com
TransMedics Group Q3 Earnings Call HighlightsTransMedics Group NASDAQ: TMDX raised its full-year revenue outlook after reporting record third-quarter revenue and transplant case volume, as gains in its liver and heart businesses helped offset a decline in U.S. deceased donor volume.
11 days ago · schaeffersresearch.com
Unusual Options Volume Report: 3 Stocks Moving After EarningsThree stocks are seeing unusual options activity following their quarterly earnings reports: DraftKings Inc (NASDAQ:DKNG), TransMedics Group Inc (NASDAQ:TMDX), and Omada Health Inc (NASDAQ:OMDA).
11 days ago · zacks.com
TransMedics (TMDX) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesWhile the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove TMDX